Stevanato

STVN

Market cap $5.09B

Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript

Stevanato Group (STVN) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.11 per share a year ago.

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2026. First Quarter of 2026 Highlights (comparisons to prior-year period) For the first quarter of 2026, revenue increased 7% (10% on a constant currency basis) to €273.6 million, with high-value solutions.

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences: Tuesday, May 12, at 8:00 a.m. (PT) - Bank of America Global Healthcare Conference in Las Vegas, NV Tuesday, June 2, at 2:40 - 3:10 p.m. (CT) – William Blair Growth Stock Conference in Chi.

Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Conestoga SMid Cap Composite returned -10.24% net-of-fees in the first quarter, lagging the Russell 2500 Growth Index's return of -3.52%. RBC's performance was driven by continued strength in aerospace and defense, where demand remains robust and increasingly visible through a growing backlog. Despite a solid quarter, Repligen stock underperformed as investors focused on a more measured outlook and lingering concerns around end-market demand.

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter 2026 on Thursday, May 7, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Thursday, May 7, 2026, to discuss finan.

While near-term results were disappointing, Conestoga Capital Small Cap Composite believes the underlying fundamentals of the portfolio companies remain intact, continuing to focus on owning high-quality businesses. LeMaitre Vascular, Inc.'s operating income increased 47% on mid-teens revenue growth as the company consistently converted steady procedure-driven demand into outsized profit growth. The mix shift toward higher-value programs supported both RBC Bearings, Inc.'s growth and profitability, with aerospace and defense revenue increasing over 40% in the quarter.

The Fund rebounded and outperformed the Russell 2000 ® Growth Index in the fourth quarter. Boot Barn's revenues and earnings handily exceeded estimates, with greater transaction volumes and new store openings. Abivax reported strong clinical trial results for its obefazimod treatment to address ulcerative colitis in a longer lasting manner.